Immunoglobulin (Ig)A nephropathy has the highest incidence among the various forms glomerulonephritis in the world. The initiating and progressive factors in patients with IgA nephropathy are still obscure. Although there is no specific treatment for patients with IgA nephropathy at present, more clinical trials of new treatments are warranted for such patients. Therefore, it is necessary to clarify those factors and to develop more effective drugs using a spontaneous animal model, the ddY mouse, in the future.
No takes yet. Share an insight, caveat, or question.
Yasuhiko Tomino (2009) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: